Septerna, Inc. Net Income
Septerna, Inc. (SEPN) reported Net Income of -$13.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-10
- Septerna, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$13.03M.
- Septerna, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$8.64M.
- Septerna, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$10.74M.
- Septerna, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $8.17M.
- Septerna, Inc. net income (loss) attributable to parent for fiscal 2025 was -$48.88M.
- Septerna, Inc. net income (loss) attributable to parent for fiscal 2024 was -$71.80M, a 1817.66% decline from fiscal 2023.
- Septerna, Inc. net income (loss) attributable to parent for fiscal 2023 was $4.18M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.03M 10-Q · filed 2026-08-10 | -$21.67M 10-Q · filed 2026-08-10 | -$32.41M derived: sum of 3 quarters · filed 2026-08-10 | -$24.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$8.64M 10-Q · filed 2026-08-10 | -$19.38M derived: sum of 2 quarters · filed 2026-08-10 | -$11.20M derived: sum of 3 quarters · filed 2026-08-10 | -$36.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$10.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$2.56M derived: sum of 2 quarters · filed 2026-03-09 | -$27.40M derived: sum of 3 quarters · filed 2026-08-10 | -$48.88M 10-K · filed 2026-03-09 |
| 2025-09-30 | $8.17M 10-Q · filed 2025-11-10 | -$16.66M derived: sum of 2 quarters · filed 2026-08-10 | -$38.14M 10-Q · filed 2025-11-10 | -$58.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$24.84M 10-Q · filed 2026-08-10 | -$46.31M 10-Q · filed 2026-08-10 | -$66.98M derived: sum of 3 quarters · filed 2026-08-10 | -$87.50M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$21.48M 10-Q · filed 2026-08-10 | -$42.14M derived: sum of 2 quarters · filed 2026-08-10 | -$62.67M derived: sum of 3 quarters · filed 2026-08-10 | -$79.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$20.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$41.19M derived: sum of 2 quarters · filed 2026-03-09 | -$57.70M derived: sum of 3 quarters · filed 2026-03-09 | -$71.80M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$20.52M 10-Q · filed 2025-11-10 | -$37.03M derived: sum of 2 quarters · filed 2025-11-10 | -$51.13M 10-Q · filed 2025-11-10 | -$16.24M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$16.51M 10-Q · filed 2025-11-10 | -$30.61M 10-Q · filed 2025-08-11 | $4.29M derived: sum of 3 quarters · filed 2025-11-10 | -$6.66M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-03-31 | -$14.10M 10-Q · filed 2025-11-10 | $20.80M derived: sum of 2 quarters · filed 2025-11-10 | $9.85M derived: sum of 3 quarters · filed 2025-11-10 | -$746.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-12-31 | $34.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $23.95M derived: sum of 2 quarters · filed 2025-03-27 | $13.35M derived: sum of 3 quarters · filed 2025-03-27 | $4.18M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$10.95M 10-Q · filed 2024-11-20 | -$21.54M derived: sum of 2 quarters · filed 2024-11-20 | -$30.71M 10-Q · filed 2024-11-20 | |
| 2023-06-30 | -$10.60M 10-Q · filed 2024-11-20 | -$19.77M derived: sum of 2 quarters · filed 2024-11-20 | ||
| 2023-03-31 | -$9.17M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |